Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Rating Upgraded by The Goldman Sachs Group

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by The Goldman Sachs Group from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Separately, Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 2.3%

Shares of OTCMKTS:SGIOY opened at $8.85 on Monday. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $15.06 billion, a price-to-earnings ratio of 11.06, a PEG ratio of 3.32 and a beta of 0.08. The stock’s 50-day moving average price is $9.70 and its two-hundred day moving average price is $9.89. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The company had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. On average, research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.